US 12,077,583 B2
Antibodies specific to human NECTIN4
Ofer Mandelboim, Shoham (IL); Adi Reches, Koranit (IL); Stipan Jonjic, Rijeka (HR); and Pinchas Tsukerman, Jerusalem (IL)
Assigned to NECTIN THERAPEUTICS LTD., Jerusalem (IL); and YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW, Jerusalem (IL)
Appl. No. 17/052,960
Filed by YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., Jerusalem (IL); and NECTIN THERAPEUTICS LTD., Jerusalem (IL)
PCT Filed May 6, 2019, PCT No. PCT/IL2019/050508
§ 371(c)(1), (2) Date Nov. 4, 2020,
PCT Pub. No. WO2019/215728, PCT Pub. Date Nov. 14, 2019.
Claims priority of provisional application 62/668,824, filed on May 9, 2018.
Prior Publication US 2021/0130459 A1, May 6, 2021
Int. Cl. C07K 16/00 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 45/06 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01)] 13 Claims
 
1. An isolated monoclonal antibody which binds to human Nectin4, or an antibody fragment thereof comprising at least the antigen binding portion, wherein the isolated antibody or antibody fragment is capable of inhibiting the binding of Nectin4 to T cell immunoreceptor with Ig and ITIM domains (TIGIT), wherein the isolated antibody or antibody fragment comprises a set of six complementarity determining regions (CDRs) selected from the group consisting of:
(i) a heavy chain (HC) CDR1 with the amino acid sequence SYYIH (SEQ ID NO: 25); a HC CDR2 with the amino acid sequence WIYPGNVNTKYNERFKG (SEQ ID NO: 26); a HC CDR3 with the amino acid sequence SNPYVMDY (SEQ ID NO: 27); a light chain (LC) CDR1 with the amino acid sequence KASQSVNNDVA (SEQ ID NO: 28); a LC CDR2 with the amino acid sequence YASNRFT (SEQ ID NO: 29); and a LC CDR3 with the amino acid sequence QQAYRSPYT (SEQ ID NO: 30);
(ii) a HC CDR1 with the amino acid sequence AYNIH (SEQ ID NO: 9), a HC CDR2 is with the amino acid sequence YIYPNNGGSGYNQKFMN (SEQ ID NO: 10), a HC CDR3 with the amino acid sequence FDYDEAWFIY (SEQ ID NO: 11), LC CDR1 is SASSSVSYMH (SEQ ID NO: 12), a LC CDR2 with the amino acid sequence DTSKLAS (SEQ ID NO: 13), and a LC CDR3 with the amino acid sequence FQGSGSPYT (SEQ ID NO: 14); and
(iii) a HC CDR1 with the amino acid sequence TYYIH (SEQ ID NO: 15), a HC CDR2 with the amino acid sequence WIYPGNVNTKNNEKFKV (SEQ ID NO: 16), a HC CDR3 with the amino acid sequence SNPYVMDY (SEQ ID NO: 17), a LC CDR1 with the amino acid sequence KASQSVSNDVA (SEQ ID NO: 18), a LC CDR2 with the amino acid sequence YASNRYT (SEQ ID NO: 19), and a LC CDR3 with the amino acid sequence QQDYSSPYT (SEQ ID NO: 20).